Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

IONS

+ Watchlist+ Portfolio

Ionis Pharmaceuticals, Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$26.96
52-Week Range
$26.55 – $86.74
Market Cap
$4.56B
P/E (TTM)
—
EPS (TTM)
-3.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
11.58
PEG Ratio
27.33
Return on Equity
-108.05%
Return on Assets
-11.88%
Gross Margin
3.00%
Operating Margin
-58.84%
Profit Margin
-56.93%
Current Ratio
5.42
Debt/Equity
5.52
Total Debt
$2.17B
Free Cash Flow
$-371.24M
Revenue Growth
54.90%
Earnings Growth
—
Enterprise Value
$4.79B

Market Snapshot

About

Ionis Pharmaceuticals is a biotechnology company pioneering RNA-targeted therapeutics. The company uses its proprietary antisense technology platform to design medicines that regulate RNA to treat diseases. Ionis has brought multiple drugs to market and has a robust pipeline targeting neurological diseases, cardiovascular conditions, and rare diseases. The company partners with major pharmaceutical firms and receives royalties from approved drugs including Spinraza for spinal muscular atrophy.